# RV001V

Source: https://onco.cc/drugs/rv001v/  
OnCo record `rv001v` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RV001V is a cancer vaccine from RhoVac APS, in registered phase 2 trials for prostate cancer.

## Summary

RV001V is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by RhoVac APS, in prostate cancer. A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: RV001V
- Modality: Cancer vaccine
- Mechanism: A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens.

## Sources

- ClinicalTrials.gov: trials of RV001V: https://clinicaltrials.gov/search?intr=RV001V

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- trials: [Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer](https://onco.cc/trials/nct04114825/)

---
JSON: https://onco.cc/api/v1/entities/rv001v.json